CHICAGO--(BUSINESS WIRE)--Celsis International plc, a Chicago-based life science products and laboratory services company, announces the addition of Drug Development Services to its growing services portfolio. These new service offerings, which include ADME-Tox studies and preclinical and clinical CMC development services, are part of the company’s long-term strategy to offer comprehensive products and services to accelerate drug discovery and development.
